2. Signaling Pathways
  3. GPCR/G Protein
    Neuronal Signaling
  4. Cannabinoid Receptor
  5. Cannabinoid Receptor Isoform
  6. Cannabinoid Receptor Agonist

Cannabinoid Receptor Agonist

Cannabinoid Receptor Agonists (27):

Cat. No. Product Name Effect Purity
  • HY-111110
    Olorinab
    		Agonist 99.29%
    Olorinab (APD 371) is a highly potent, selective and fully efficacious cannabinoid receptor type 2 (CB2) agonist, with an EC50 of 6.2 nM for hCB2.
  • HY-16642A
    LY2828360
    		Agonist 98.41%
    LY2828360 is a slowly acting but efficacious G protein-biased cannabinoid (CB2) agonist, inhibiting cAMP accumulation and activating ERK1/2 signaling.
  • HY-110036A
    GW405833 hydrochloride
    		Agonist 99.59%
    GW405833 hydrochloride is a potent and selective cannabinoid-2 (CB2) receptor agonist (EC50 = 0.65 nM; maximum inhibition = 44.6%). GW405833 hydrochloride produces potent antihyperalgesic effects in several rodent models of pain.
  • HY-14167
    GW842166X
    		Agonist 99.97%
    GW842166X is a potent and selective cannabinoid receptor 2 (CB2) agonist with IC50 values of 63 and 91 nM for human and rat CB2, respectively.
  • HY-15451
    MDA 19
    		Agonist 99.26%
    MDA 19 is a potent and selective agonist of human cannabinoid receptor 2 (CB2), with a Ki of 43.3 nM. MDA 19 has antiallodynic effects in a rat model of neuropathic pain and does not affect rat locomotor activity.
  • HY-145604
    Vicasinabin
    		Agonist 98.37%
    Vicasinabin (RG7774) is the potent agonist of cannabinoid receptor 2 (CB2). Vicasinabin has the potential for the research of human diseases including chronic pain, atherosclerosis, regulation of bone mass, neuroinflammation, and other related diseases (extracted from patent US20130116236A1).
  • HY-148137
    CB1 agonist 1
    		Agonist 99.84%
    CB1 agonist 1 (compound 22) is an agonist of CB1. CB1 agonist 1 shows affinity to CB1 receptor with an pIC50 value of 5.7. CB1 agonist 1 can be used for the research of brain disorders.
  • HY-145153
    S-777469
    		Agonist 98.83%
    S-777469 is a selective and orally available cannabinoid type 2 receptor (CB2) agonist with a Ki of 36 nM. S-777469 significantly suppresses compound 48/80-induced scratching behavior in mice in a dose-dependent manner. S-777469 produces its antipruritic effects by inhibiting itch signal transmission through CB2 agonism.
  • HY-W011051S
    2-Arachidonoylglycerol-d8
    		Agonist ≥98.0%
    2-Arachidonoylglycerol-d8 is the deuterium labeled 2-Arachidonoylglycerol. 2-Arachidonoylglycerol is a second endogenous cannabinoid ligand in the central nervous system.
  • HY-135882
    OMDM-6
    		Agonist
    OMDM-6 is a hybrid agonist of vanilloid receptor type 1 (VR1, TRPV1) (EC50=75 nM) and cannabinoid receptor type 1 (CB1) (Ki=3.2 μM). OMDM-6 inhibits anandamide cellular uptake (ACU) with a Ki of 7.0 μM.
  • HY-W011051S1
    2-Arachidonoylglycerol-d5
    		Agonist ≥99.0%
    2-Arachidonoylglycerol-d5 is the deuterium labeled 2-Arachidonoylglycerol. 2-Arachidonoylglycerol is a second endogenous cannabinoid ligand in the central nervous system.
  • HY-110050
    GP1a
    		Agonist 99.66%
    GP1a is a potent agonist of cannabinoid receptor 2 (CB2). Gp1a is beneficial to skin wound healing. GP1a inhibits inflammation and fibrogenesis while promoting re-epithelialization.
  • HY-15420
    BML-190
    		Agonist 99.54%
    BML-190(IMMA) is a potent and selective CB2 receptor ligand (Ki values are 435 nM and > 2 μM for CB2 and CB1 respectively).
  • HY-12761
    A-836339
    		Agonist 99.61%
    A-836339 is a cannabinoid CB2 receptor-selective agonist; exhibits high potencies at CB(2) and selectivity over CB(1) receptors.
  • HY-110047
    CB65
    		Agonist
    CB65 is a potent and high affinity CB2 selective agonist with a Ki value of 3.3 nM. CB65 exhibits a Ki of >1000 nM for CB1 receptor.
  • HY-107471
    CB2 receptor agonist 3
    		Agonist 99.86%
    CB2 receptor agonist 3 is a robust and selective CB2 cannabinoid agonist with Kis of 7.6 and 900 nM for CB2 and CB1, respectively. CB2 receptor agonist 3 significantly increases P-ERK 1/2 expression in HL-60 cells.
  • HY-N1415S
    β-Caryophyllene-d2
    		Agonist
    β-Caryophyllene-d2 is deuterium labeled β-Caryophyllene. β-Caryophyllene is a CB2 receptor agonist.
  • HY-124283A
    LEI-101
    		Agonist
    LEI-101 is a potent, selective, and orally bioavailable cannabinoid CB2 receptor agonist, with a pEC50 of 8 for hCB2, and a pKi of less than 4 for hERG. LEI-101 is ~100-fold more potent in binding to CB2 receptors than to CB1 receptors.
  • HY-W751734
    HU 433
    		Agonist
    HU 433 is a synthetic cannabinoid CB2 receptor agonist that is an enantiomer of HU 308. HU 433 exerts its anti-inflammatory and neuroprotective effects by binding to the CB2 receptor. CB2 receptor is mainly expressed on immune cells, and its activation can regulate immune response and inflammatory processes. HU 433 can also affect microglial signaling pathways, especially LPS and IFNγ-mediated signaling pathways, including the phosphorylation of MAPKs (mitogen activated protein kinases) such as ERK1/2, JNK, p38 and Akt. HU 433 can be used in the study of neuroinflammation and retinal diseases.
  • HY-14160
    CB2 receptor agonist 7
    		Agonist
    CB2 receptor agonist 7 (Compound 5B) is a cannabinoid 2 (CB2) receptor agonist with blood-brain barrier permeability.